Nxera Pharma Co., Ltd. (TYO: 4565)
Japan flag Japan · Delayed Price · Currency is JPY
1,202.00
+8.00 (0.67%)
Nov 12, 2024, 3:40 PM JST

Nxera Pharma Company Description

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.

Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications.

The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.

It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs.

Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions.

Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Nxera Pharma Co., Ltd.
Country Japan
Founded 1990
Industry Biotechnology
Sector Healthcare
Employees 350
CEO Christopher Cargill

Contact Details

Address:
PMO Hanzomon
Tokyo, 102-0083
Japan
Phone 81 3 5210 3290
Website nxera.life

Stock Details

Ticker Symbol 4565
Exchange Tokyo Stock Exchange
Fiscal Year January - December
Reporting Currency JPY
ISIN Number JP3431300007
SIC Code 2836

Key Executives

Name Position
Christopher Cargill Chief Executive Officer
Hironoshin Nomura Chief Financial Officer
Toshihiro Maeda Chief Operating Officer